Johnson and Johnson Innovation logo

HiFiBiO partners with Johnson & Johnson Innovation

In Uncategorized by nagrazodar

Paris, 12 June 2015—Janssen and HiFiBiO ARE COLLABORATING TO evaluate HiFiBiO’s single cell technology

“Exploring New Antibody Discovery Platforms – While current antibody discovery technologies, such as hybridomas, are highly reliable, they are also inefficient in terms of percentage of antigen-specific B cells identified during screening. HiFiBiO and Janssen Biotech, Inc. are collaborating to evaluate the company’s single cell technology for genetically characterizing individual cells as a potential new antibody discovery platform. Validation activities include comparing a large repertoire of B-cell antibodies from a number of different tissues generated against a target antigen chosen by Janssen Research & Development, LLC.”

[Download the full press release [PDF, 73K]]